MOUNTAIN VIEW, Calif., Dec. 18, 2013 /PRNewswire/ -- Tissue engineering is a rapidly diversifying technology that emerged as a regenerative or reparative medicine with potential to circumvent organ shortage globally. Extensive developments in tissue engineering, which involve leveraging technologies from biomaterials, molecular medicine, biochemistry, nanotechnology, genetic, and biomedical engineering, target the restructure and/or repair of human organs through regeneration and cell expansion.
In recent years, cell-based technologies and the integration of genetics – with the use of biological substitutes that aim to restore, maintain or enhance tissue function – have been a popular approach for tissue regeneration and reparation treatment, according to Frost & Sullivan's Advances in Tissue Engineering and Organ Regeneration: Technology Market Penetration and Roadmapping analysis (http://www.technicalinsights.frost.com).
For more information on this research, please email Jennifer Carson, Corporate Communications, at firstname.lastname@example.org.
Tissue engineering has been a field marked by extensive research and development (R&D), and companies take several years to commercially launch products.
"Still considered a nascent science, research in the field has offered and continues to offer an increasing number of substitutes for applications that would enable the human body to withstand pain and injuries," said Frost & Sullivan Technical Insights Industry Analyst Darshana De. "Apart from previous applications such as the common regeneration of bone, cartilage and skin, current targets have expanded to cardiovascular, kidney, pancreas, liver, spine, ligament, esophagus, cornea, thoracic, lung, nerve, lymphatic and blood vessels."
|SOURCE Frost & Sullivan|
Copyright©2012 PR Newswire.
All rights reserved